IKT
#3412
Inhibikase Therapeutics, Inc. - Common Stock
2.2 2 USD
+0.13%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
Year Range
Daily Change
+13.27%
Monthly Change
+30.59%
6 month change
+30.59%
Year Change
+14.43%
Previous Close
1.9 6
Open
2.2 1
Low
2.2 0
High
2.3 6
Volume
1 312
Financials
- Market Capitalization 293.11 M
- Employee 35
- Founded 2008
- CEO N/A
- Website www.inhibikase.com
- Headquarter Delaware, United States
- FIGI BBG005TP2339
- Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-4.18
Price to sales ratio
53.93
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 3387 |  TTRX Turn Therapeutics Inc. - Common Stock | 9.52 USD | +0.53% | +12.93% | +54.05% | -4.80% | 283.58 M USD | ||
| 3404 |  MGNX MacroGenics, Inc. - Common Stock | 4.37 USD | -2.89% | -6.62% | +10.35% | +178.34% | 277.77 M USD | ||
| 3416 |  GLSI Greenwich LifeSciences, Inc. - Common stock | 18.61 USD | +0.22% | -7.87% | -23.79% | +74.09% | 273.16 M USD | ||
| 3417 |  NAGE Niagen Bioscience, Inc. - Common Stock | 3.37 USD | -2.88% | -4.26% | -3.16% | -32.33% | 268.40 M USD |
Frequently asked questions about Inhibikase Therapeutics, Inc. - Common Stock
What is the Inhibikase Therapeutics, Inc. - Common Stock stock price today?
The current price of Inhibikase Therapeutics, Inc. - Common Stock (IKT) is 2.22. Over the past 24 hours, the stock has changed by +13.27%. Follow the IKT chart for real-time price dynamics.
What is the stock ticker of Inhibikase Therapeutics, Inc. - Common Stock?
Inhibikase Therapeutics, Inc. - Common Stock trades under the ticker IKT. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Inhibikase Therapeutics, Inc. - Common Stock stock going up?
IKT has changed by +6.22% over the last week, +30.59% over the last month, and +14.43% over the last year. Review the chart to see whether the current move is part of a broader trend.
What was Inhibikase Therapeutics, Inc. - Common Stock net income for the last quarter?
Inhibikase Therapeutics, Inc. - Common Stock reported net income of -16.38 M for the last quarter. The previous quarter showed -12.73 M, which means net income changed by -28.63%.
How many employees does Inhibikase Therapeutics, Inc. - Common Stock have?
As of the latest available data, Inhibikase Therapeutics, Inc. - Common Stock has 35 employees. Workforce size can provide additional context about the company's scale and operations.
What is Inhibikase Therapeutics, Inc. - Common Stock EBITDA?
Inhibikase Therapeutics, Inc. - Common Stock EBITDA is -16.38 M, and its EBITDA margin is -1 121.15%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Inhibikase Therapeutics, Inc. - Common Stock stock?
You can buy Inhibikase Therapeutics, Inc. - Common Stock (IKT) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Inhibikase Therapeutics, Inc. - Common Stock stock?
Investing in Inhibikase Therapeutics, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the IKT chart and related analysis on metatrader.com as part of your research.